FI56533C - Saett att framstaella nya 4alfa-karbamyloxi-8-alkoxi-10-metylen-3-metyl-2,9-dioxatricyklo(4,3,1,03,7)-dekaner - Google Patents
Saett att framstaella nya 4alfa-karbamyloxi-8-alkoxi-10-metylen-3-metyl-2,9-dioxatricyklo(4,3,1,03,7)-dekaner Download PDFInfo
- Publication number
- FI56533C FI56533C FI3983/73A FI398373A FI56533C FI 56533 C FI56533 C FI 56533C FI 3983/73 A FI3983/73 A FI 3983/73A FI 398373 A FI398373 A FI 398373A FI 56533 C FI56533 C FI 56533C
- Authority
- FI
- Finland
- Prior art keywords
- methyl
- methylene
- dioxatricyclo
- formula
- carbamyloxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 16
- 239000000932 sedative agent Substances 0.000 claims description 8
- 230000001624 sedative effect Effects 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 3
- 239000012948 isocyanate Substances 0.000 claims description 3
- 150000002513 isocyanates Chemical class 0.000 claims description 3
- 229910052987 metal hydride Inorganic materials 0.000 claims description 3
- 150000004681 metal hydrides Chemical class 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- MKJDUHZPLQYUCB-UHFFFAOYSA-N decan-4-one Chemical compound CCCCCCC(=O)CCC MKJDUHZPLQYUCB-UHFFFAOYSA-N 0.000 claims description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 2
- 206010008631 Cholera Diseases 0.000 claims 1
- 239000000956 alloy Substances 0.000 claims 1
- 229910045601 alloy Inorganic materials 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- 230000003533 narcotic effect Effects 0.000 description 7
- 206010002091 Anaesthesia Diseases 0.000 description 6
- 230000037005 anaesthesia Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- -1 2a) Chemical compound 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- HXBPYFMVGFDZFT-UHFFFAOYSA-N allyl isocyanate Chemical compound C=CCN=C=O HXBPYFMVGFDZFT-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 229940125723 sedative agent Drugs 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- GSLTVFIVJMCNBH-UHFFFAOYSA-N 2-isocyanatopropane Chemical compound CC(C)N=C=O GSLTVFIVJMCNBH-UHFFFAOYSA-N 0.000 description 1
- SZMBUJZDELWSAV-UHFFFAOYSA-N 8-methoxy-3-methyl-10-methylidene-2,9-dioxatricyclo[4.3.1.03,7]decan-4-one Chemical compound COC1C2C3CC(C2(OC(O1)C3=C)C)=O SZMBUJZDELWSAV-UHFFFAOYSA-N 0.000 description 1
- 241000234282 Allium Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- YMUQRQKYYOWGPN-SLEGRLQASA-N Sarracine Chemical compound C1C[C@H](COC(=O)C(\CO)=C/C)[C@@H]2[C@H](OC(=O)C(\C)=C/C)CCN21 YMUQRQKYYOWGPN-SLEGRLQASA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- SMZOGRDCAXLAAR-UHFFFAOYSA-N aluminium isopropoxide Chemical compound [Al+3].CC(C)[O-].CC(C)[O-].CC(C)[O-] SMZOGRDCAXLAAR-UHFFFAOYSA-N 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical group O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940112021 centrally acting muscle relaxants carbamic acid ester Drugs 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- KQWGXHWJMSMDJJ-UHFFFAOYSA-N cyclohexyl isocyanate Chemical compound O=C=NC1CCCCC1 KQWGXHWJMSMDJJ-UHFFFAOYSA-N 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- DGTNSSLYPYDJGL-UHFFFAOYSA-N phenyl isocyanate Chemical compound O=C=NC1=CC=CC=C1 DGTNSSLYPYDJGL-UHFFFAOYSA-N 0.000 description 1
- 229940096826 phenylmercuric acetate Drugs 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 210000001034 respiratory center Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Anesthesiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI791977A FI58776C (fi) | 1973-02-08 | 1979-06-20 | Saett att framstaella nya 4alfa-karbamyloxi-8-alkoxi-3,10-dimetyl-2,9-dioxatricyklo-(4,3,1,03,7)-dekaner med lugnande och narkotisk verkan |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2306118A DE2306118C3 (de) | 1973-02-08 | 1973-02-08 | S-Methyl-lO-methylen^-dioxatricyclo [43,1,037I decane und 3,10-Dimethyl2,9-dioxatricyclo [43,1, 03·7! decane sowie Verfahren zu deren Herstellung |
| DE2306118 | 1973-02-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FI56533B FI56533B (fi) | 1979-10-31 |
| FI56533C true FI56533C (fi) | 1980-02-11 |
Family
ID=5871280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI3983/73A FI56533C (fi) | 1973-02-08 | 1973-12-27 | Saett att framstaella nya 4alfa-karbamyloxi-8-alkoxi-10-metylen-3-metyl-2,9-dioxatricyklo(4,3,1,03,7)-dekaner |
Country Status (20)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2719916C2 (de) | 1977-05-04 | 1987-03-19 | Kali-Chemie Pharma Gmbh, 3000 Hannover | Verfahren zur Herstellung von 2,9-Dioxatricyclo[4,3,1,0↑3↑↑,↑↑7↑]decanen |
| RU2494102C1 (ru) * | 2012-08-15 | 2013-09-27 | ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ НАУКИ ИНСТИТУТ ОРГАНИЧЕСКОЙ ХИМИИ им. Н.Д. ЗЕЛИНСКОГО РОССИЙСКОЙ АКАДЕМИИ НАУК (ИОХ РАН) | Способ получения замещенных 2,3,5,6-тетраоксабицикло[2.2.1]гептанов |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2027890C3 (de) * | 1970-06-06 | 1979-02-01 | Kali Chemie Ag | 8-AIkoxy oder -Benzyloxy-3-methyl-lO- methylen-2,9-dioxatricyclo-(43,l,03,7 )-decan-4-one und 8-AIkoxy oder 8-Benzyloxy-3,10-dimethyl-2,9dioxatricyclo- (43,1,O" )-decan-4-one |
| DE2129507C3 (de) * | 1971-06-15 | 1980-02-14 | Kali-Chemie Ag, 3000 Hannover | Verfahren zur Herstellung von 8-Alkoxy-3halogenmethyl-4-acetoxy- 10-methylen-2,9dioxatricyclo(43,l,03 7 )decanen |
-
1973
- 1973-12-27 FI FI3983/73A patent/FI56533C/fi active
-
1974
- 1974-01-08 CH CH19374A patent/CH603657A5/xx not_active IP Right Cessation
- 1974-01-11 NL NLAANVRAGE7400404,A patent/NL183011C/xx not_active IP Right Cessation
- 1974-01-18 GB GB254874A patent/GB1436821A/en not_active Expired
- 1974-01-31 BE BE140441A patent/BE810475A/xx not_active IP Right Cessation
- 1974-02-01 ES ES422841A patent/ES422841A1/es not_active Expired
- 1974-02-04 IE IE196/74A patent/IE38815B1/xx unknown
- 1974-02-05 HU HUKA1402A patent/HU169556B/hu unknown
- 1974-02-05 IL IL44145A patent/IL44145A/en unknown
- 1974-02-05 JP JP49014830A patent/JPS5750793B2/ja not_active Expired
- 1974-02-06 CS CS815A patent/CS175472B2/cs unknown
- 1974-02-06 DD DD176411A patent/DD109872A5/xx unknown
- 1974-02-07 SU SU7401998126A patent/SU576939A3/ru active
- 1974-02-07 NO NO740403A patent/NO140981C/no unknown
- 1974-02-07 SE SE7401645A patent/SE403115B/xx unknown
- 1974-02-07 AT AT97574*#A patent/AT332397B/de not_active IP Right Cessation
- 1974-02-07 FR FR7404118A patent/FR2217008B1/fr not_active Expired
- 1974-02-08 ZA ZA00740845A patent/ZA74845B/xx unknown
- 1974-02-08 CA CA192,121A patent/CA1025873A/en not_active Expired
- 1974-02-08 PH PH15490A patent/PH12696A/en unknown
-
1975
- 1975-03-03 SU SU752109640A patent/SU659086A3/ru active
- 1975-04-09 SU SU752121560A patent/SU648562A1/ru active
-
1976
- 1976-04-21 SU SU762347297A patent/SU643503A1/ru active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0090341B1 (de) | Spiro(4.(3+n))-2-aza-alkan-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und ihre Verwendung | |
| Harris et al. | The synthesis of tenuazonic and congeneric tetramic acids | |
| EP3619214B1 (en) | Gamma-spiroketal-gamma-lactones and pharmaceutical composition containing same and process for preparation thereof | |
| FR2489319A1 (fr) | Derives de l'acide amino-4 butyrique et les medicaments, actifs notamment sur le systeme nerveux central, en contenant | |
| DE2951200A1 (de) | Ketal- und thioketalderivate von mercaptoacylprolinen und -pipecolinsaeuren, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von hochdruck | |
| EP0003056A1 (de) | N-substituierte omega-Aminoalkanoyl-omega-aminoalkansäuren, ihre Verwendung und Verfahren zu ihrer Herstellung sowie diese Verbindungen enthaltende Arzneimittel | |
| HU189991B (en) | Process for producing benzene derivatives with four substituents | |
| US4254146A (en) | 3-Benzoyl-2-nitrophenylacetic acids, metal salts, amides and esters | |
| Groth et al. | Asymmetric synthesis of D-erythro-sphingosine | |
| SK280776B6 (sk) | Benzomorfány, spôsob ich výroby, farmaceutické pro | |
| SU1318161A3 (ru) | Способ получени пиперазиновых производных или их фармацевтически приемлемых солей (его варианты) | |
| FI56533C (fi) | Saett att framstaella nya 4alfa-karbamyloxi-8-alkoxi-10-metylen-3-metyl-2,9-dioxatricyklo(4,3,1,03,7)-dekaner | |
| EP0057881A2 (en) | An anti-inflammatory, analgesic, and antipyretic pharmaceutical composition, and method for producing it | |
| US4088668A (en) | Acetylene derivatives | |
| CA1097684A (fr) | PROCEDE DE PREPARATION D'ACIDES.gamma.ARYL .gamma.OXO ISOVALERIQUES | |
| FR2470770A1 (fr) | Nouveaux ethers de b-imidazolylethyle de quinoleine-2 ou 4-methanols, utiles notamment comme antimicrobiens, et leur procede de preparation | |
| DD243277A5 (de) | Verfahren zur herstellung neuer 3-phenyl-2-propenamin-derivate | |
| GB1563252A (en) | Spirolactams | |
| US3576009A (en) | Amphetamine derivatives | |
| FI63755B (fi) | Foerfarande foer framstaellning av foer skoetseln av levern avedda 1-(2',4',6'-trihydroksifenyl)-propandion-(1,2)-foere nigar | |
| FR2668152A1 (fr) | Derives n,o spirocycliques de cyclotriphosphazenes, leur preparation et leur application en therapeutique. | |
| FI58776C (fi) | Saett att framstaella nya 4alfa-karbamyloxi-8-alkoxi-3,10-dimetyl-2,9-dioxatricyklo-(4,3,1,03,7)-dekaner med lugnande och narkotisk verkan | |
| CA1105053A (fr) | Sulfamido acetyleniques de benzamides utilisables en therapeutique | |
| US3374265A (en) | Diphenyl hydroxy carbamate compounds | |
| RU2131247C1 (ru) | Фармацевтическая композиция и производные l-аминокислот, обладающие гепатопротекторным действием |